PZKKN-94 is a dual serotonin 5-HT1B receptor agonist and serotonin 5-HT6 receptor antagonist which is under investigation for the potential treatment of Parkinson's disease. Its values were 39 nM (EC50Tooltip half-maximal effective concentration) and 88.1% (EmaxTooltip maximal efficacy) at the serotonin 5-HT1B receptor and 7.7 nM (KB) at the serotonin 5-HT6 receptor. The drug showed selectivity for these receptors over 43 other targets. It shows favorable drug-like properties. In rodents, PZKKN-94 shows antiparkinsonian-like, pro-cognitive, and antidepressant-like effects. PZKNN-94 was first described in the scientific literature by Paweł Zajdel and colleagues in 2025.
See also List of investigational Parkinson's disease drugs
References